These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 14695836)

  • 1. Characteristic physical properties and structural fragments of marketed oral drugs.
    Vieth M; Siegel MG; Higgs RE; Watson IA; Robertson DH; Savin KA; Durst GL; Hipskind PA
    J Med Chem; 2004 Jan; 47(1):224-32. PubMed ID: 14695836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time-related differences in the physical property profiles of oral drugs.
    Leeson PD; Davis AM
    J Med Chem; 2004 Dec; 47(25):6338-48. PubMed ID: 15566303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of physiochemical property profiles of development and marketed oral drugs.
    Wenlock MC; Austin RP; Barton P; Davis AM; Leeson PD
    J Med Chem; 2003 Mar; 46(7):1250-6. PubMed ID: 12646035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolution of synthetic oral drug properties.
    Proudfoot JR
    Bioorg Med Chem Lett; 2005 Feb; 15(4):1087-90. PubMed ID: 15686918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The graphical representation of ADME-related molecule properties for medicinal chemists.
    Ritchie TJ; Ertl P; Lewis R
    Drug Discov Today; 2011 Jan; 16(1-2):65-72. PubMed ID: 21074634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Physicochemical Properties for Drugs of Natural Origin.
    Camp D; Garavelas A; Campitelli M
    J Nat Prod; 2015 Jun; 78(6):1370-82. PubMed ID: 26039921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs in other drugs: a new look at drugs as fragments.
    Siegel MG; Vieth M
    Drug Discov Today; 2007 Jan; 12(1-2):71-9. PubMed ID: 17198975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escape from flatland: increasing saturation as an approach to improving clinical success.
    Lovering F; Bikker J; Humblet C
    J Med Chem; 2009 Nov; 52(21):6752-6. PubMed ID: 19827778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Strategy of molecular design of drugs: the unification of macro-properties and micro-structures of a molecule].
    Guo ZR
    Yao Xue Xue Bao; 2008 Mar; 43(3):227-33. PubMed ID: 18630256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption classification of oral drugs based on molecular surface properties.
    Bergström CA; Strafford M; Lazorova L; Avdeef A; Luthman K; Artursson P
    J Med Chem; 2003 Feb; 46(4):558-70. PubMed ID: 12570377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular properties that influence the oral bioavailability of drug candidates.
    Veber DF; Johnson SR; Cheng HY; Smith BR; Ward KW; Kopple KD
    J Med Chem; 2002 Jun; 45(12):2615-23. PubMed ID: 12036371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?
    Giordanetto F; Kihlberg J
    J Med Chem; 2014 Jan; 57(2):278-95. PubMed ID: 24044773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of ligand efficiency metrics in drug discovery.
    Hopkins AL; Keserü GM; Leeson PD; Rees DC; Reynolds CH
    Nat Rev Drug Discov; 2014 Feb; 13(2):105-21. PubMed ID: 24481311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of known drug space. Natural products, their derivatives and synthetic drugs.
    Bade R; Chan HF; Reynisson J
    Eur J Med Chem; 2010 Dec; 45(12):5646-52. PubMed ID: 20888084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dependence of molecular properties on proteomic family for marketed oral drugs.
    Vieth M; Sutherland JJ
    J Med Chem; 2006 Jun; 49(12):3451-3. PubMed ID: 16759087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular inflation, attrition and the rule of five.
    Leeson PD
    Adv Drug Deliv Rev; 2016 Jun; 101():22-33. PubMed ID: 26836397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physical chemical considerations of lipid-based oral drug delivery--solid lipid nanoparticles.
    Bummer PM
    Crit Rev Ther Drug Carrier Syst; 2004; 21(1):1-20. PubMed ID: 15099183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality guidelines for oral drug candidates: dose, solubility and lipophilicity.
    Bayliss MK; Butler J; Feldman PL; Green DV; Leeson PD; Palovich MR; Taylor AJ
    Drug Discov Today; 2016 Oct; 21(10):1719-1727. PubMed ID: 27423371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.